biostudies-literatureUnknown17(17)Parente P<h4>Introduction</h4>Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer-related death worldwide. CRC is characterized by morphologic and biological heterogeneity, and molecular profiling is required to select appropriate treatment in the metastatic setting. Mutations in <i>KRAS</i> are detected in approximately 40% of CRCs, with prognostic and predictive value, and with the most frequent being p.G12D. Nonetheless, there are few data on the morphologic features in <i>KRAS</i>-mutated CRCs.<h4>Materials and methods</h4>We retrospectively collected clinicopathological features and molecular profiles of CRCs in a multicenter cohort.<h4>Results</h4>A total of 2816 patients from 12 centers were included. <i>KRAS</i> mutation was found in 47.4% of cases; Cancers2721https://www.ebi.ac.uk/biostudies/studies/S-EPMC12427293biostudies-literature&lt;i&gt;KRAS&lt;/i&gt; Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to &lt;i&gt;Gly12Asp&lt;/i&gt; in a Multicenter GIPAD Real-World Study.PMC12427293Antoci FAscione AAmbrosio MRGafa RPasculli BPilozzi EVasuri FVanoli AParente PGiobbe MFassan MGrillo FAdotti FMacciomei MCMastracci LLanza GPetrelli FAngerilli VGasparello JCaputo AGandolfi LMelocchi LParrella PScarpino SVeccia NSaragoni Lfalse&lt;i&gt;KRAS&lt;/i&gt; Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to &lt;i&gt;Gly12Asp&lt;/i&gt; in a Multicenter GIPAD Real-World Study.<h4>Introduction</h4>Colorectal cancer (CRC) is the third most frequent malignancy and the second cause of cancer-related death worldwide. CRC is characterized by morphologic and biological heterogeneity, and molecular profiling is required to select appropriate treatment in the metastatic setting. Mutations in <i>KRAS</i> are detected in approximately 40% of CRCs, with prognostic and predictive value, and with the most frequent being p.G12D. Nonetheless, there are few data on the morphologic features in <i>KRAS</i>-mutated CRCs.<h4>Materials and methods</h4>We retrospectively collected clinicopathological features and molecular profiles of CRCs in a multicenter cohort.<h4>Results</h4>A total of 2816 patients from 12 centers were included. <i>KRAS</i> mutation was found in 47.4% of cases; 2025-01-01T00:00:00Z2025 Aug2026-04-23T03:19:04.592Z2026-04-23T03:11:23.844ZS-EPMC124272934094081810.3390/cancers17172721